Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 56Triple Negative Breast Neoplasms 14Sarcoma 7Neoplasm Metastasis 6Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Prostatic Neoplasms 2Inflammatory Breast Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Liposarcoma 1Leiomyosarcoma 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1

Interventions

Cyclophosphamide 11Vincristine 9Temozolomide 7Magnetic Resonance Spectroscopy 6Irinotecan 6Filgrastim 6Etoposide 6Doxorubicin 6X-Rays 5Phantoms, Imaging 5Ifosfamide 5Dactinomycin 5cixutumumab 4Vinorelbine 4Specimen Handling 4Sirolimus 4Nuclear Medicine Department, Hospital 4Melphalan 4Gemcitabine 4pegfilgrastim 3palbociclib 3Tacrolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Dexrazoxane 3Biopsy 3ulixertinib 2tipifarnib 2thymoglobulin 2temsirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Rhabdomyosarcoma × eribulin × Clear all
NCT03441360 2022-10-05

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Eisai Inc.

Phase 2 Completed
23 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡